Liposomal NAD+,
does it really help with Increased cellular energy and mitochondrial vitality?
research showsA 2026 direct oral NAD+ RCT randomized 60 participants and analyzed about 50 in the primary cohort. Whole-blood intracellular NAD rose 53% after five days, while plasma NAD did not change. Wellbeing, vitality, and wearable outcomes were all null after multiplicity correction, and the formulation was not liposomal. Actual vitality efficacy supports D with 26 points.
ads claimAdvertisements combine cellular energy, maximized absorption, mitochondrial activation, and healthy aging. The key leap is treating the intracellular role of NAD+ and general claims about liposomes as proof that the finished product works in humans.
Useful facts when choosing a product
- Korean cross-border marketplaces sell liposomal capsules and liquids claiming about 100-500 mg NAD+ per daily serving.
- Some products labeled NAD+ actually use NR or NMN as the main ingredient, while others contain NAD+ itself; the chemical name in Supplement Facts matters.
- One Codeage product provides 500 mg NAD+ plus 102.5 mg anhydrous betaine per two capsules, so it is not an NAD+-only product.
- Without product-specific data on liposome size, encapsulation efficiency, stability, and release after digestion, the word liposomal cannot establish comparative absorption.
What the research actually shows
The 2026 Kornilov RENEWAL-NAD+ trial, NCT07336836, randomized 60 healthy adults aged 45–75 and used 50 in the primary analysis. After five days of non-liposomal LathMized NAD+, whole-blood intracellular NAD increased 53% versus placebo, while plasma NAD was not significant. No clinical, vital-sign, wellbeing, wearable-activity, or sleep endpoint survived multiplicity correction. The BioNADrx/Bryleos-funded study is a preprint and was retrospectively registered on January 4, 2026 after conduct in 2022. No product-specific human efficacy trial of liposomal NAD+ exists, and evidence from NR, NMN, or NADH is not transferred because these are different compounds.
Why this is classified as D (26)
A direct oral NAD+ RCT rules out an ungraded verdict, but only the intracellular NAD surrogate was positive; actual vitality, wellbeing, and wearable outcomes were all null after correction. A non-liposomal formulation, manufacturer funding, retrospective registration, preprint status, and absence of a liposomal product trial support D with 26 points.
Counterpoint. Delivery to intracellular NAD pools is a separate C subclaim, while actual vitality efficacy remains D.
Rejudgment record. Reassessment (cross-check reflected) — A direct oral NAD+ RCT found a positive intracellular surrogate but null plasma, vitality, wellbeing, and wearable outcomes; non-liposomal formulation, manufacturer-funded preprint, retrospective registration, and no liposomal product trial
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Delivery to circulating or intracellular NAD+ pools (surrogate) | C | A direct oral NAD+ RCT found a 53% rise in intracellular NAD, but used a non-liposomal formulation, found no plasma NAD effect, and remains a manufacturer-funded preprint |
| Improved cellular energy, vitality, or wellbeing | D | Vitality and wellbeing outcomes were all null after multiplicity correction, and no product-specific human trial of liposomal NAD+ exists |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kornilov SA et al. 2026 | Randomized double-blind placebo-controlled phase 0/1b RCT preprint | 50 | BioNADrx d.b.a. Bryleos; multiple authors had equity or advisory relationships | Whole-blood intracellular NAD, plasma NAD, wellbeing, vital signs, wearable activity, and sleep | Intracellular NAD increased 53% after five days, plasma NAD was null, and no clinical, vital-sign, wellbeing, or wearable endpoint survived multiplicity correction. | Key |
| Freeberg et al. 2023 | Narrative review | Academic institutions | NAD+ concentrations and physiological function | Human studies mainly concern precursors, and whether raising NAD+ improves physiological function remains unclear. | Boundary | |
| Rodriguez-Cetina Biefer et al. 2002 | Caco-2 cell experiment | Unknown | Oxygen consumption after immune stimulation | Liposomal NAD+ preserved cellular oxygen consumption, but this was not a human absorption or efficacy trial. | Directness boundary | |
| NCT07336836 | Retrospectively registered short phase 0/1b RCT | 60 | BioNADrx Holdings, Inc. Bryleos | Intracellular and plasma NAD, multi-omics, and safety | The non-liposomal oral NAD+ trial conducted in 2022 was registered on January 4, 2026 and was not a liposomal product trial. | Directness boundary |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-17).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none
Cite this verdict
[Chamgap] Liposomal NAD+ x cellular energy and mitochondrial vitality — Evidence Grade D·26. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/liposomal-nad-cellular-energy-mitochondria/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.